Results 181 to 190 of about 111,189 (247)

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis ‐ To Suppress or Not to Suppress?

Alimentary Pharmacology &Therapeutics, EarlyView.
Individualized assessment identifies patients with decompensated autoimmune hepatitis cirrhosis who are likely to benefit from a time‐limited trial of immunosuppression versus those requiring immediate liver transplant evaluation. Early objective response monitoring (bilirubin, MELD‐Na and AST/ALT) guides continuation of immunosuppression, promotes ...
Pedro Robson Costa Passos, Valbert Oliveira Costa Filho, Guilherme Grossi Lopes Cançado   +2 more
wiley   +1 more source

Real-world experience with tabelecleucel. [PDF]

Blood Adv
Nagler A.
europepmc   +1 more source

Machine learning‐driven investigation on liquid–liquid phase separation‐related prognostic signature in diffuse large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Diffuse large B‐cell lymphoma (DLBCL) is the most common aggressive non‐Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid–liquid phase separation (LLPS)‐related prognostic model to improve risk stratification.
Zhen‐Zhong Zhou, Jia‐Chen Lu, Zhao Wang, Rong‐Hui Chen, Hai‐Long Li, Wan‐Ting Chen, Yu‐Ning Deng, Hui‐Juan Zhang, Yu Wang, Xuan‐Ye Zhang, Wei‐Juan Huang, Xiao‐Peng Tian   +11 more
wiley   +1 more source

Real-World Effectiveness of Biologic and Targeted Synthetic Therapies in Rheumatoid Arthritis: a Multicenter Study from Rheumatoid Arthritis Saudi Database (RASD). [PDF]

Open Access Rheumatol
Almoallim HM, Bahlas SM, Bawazir Y, Hussein AH, Attia GM, Manasfi H, Bafadhl ZA, Asiri AM, Ali AR, Alomair MM, Alsharaif MM, Almalki HH, Siddiqui MI, Alhazmi AS, Attar SM.   +14 more
europepmc   +1 more source

Metabolic heterogeneity‐based radiomic model predicts treatment outcomes of primary mediastinal B‐cell lymphoma patients in the IELSG37 study

British Journal of Haematology, EarlyView.
Summary Early identification of patients at risk of failing first‐line therapy remains a key challenge in primary mediastinal B‐cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL.
L. Ceriani, L. Milan, L. Cascione, A. Di Rocco, I. Kryachok, A. J. Davies, A. Stathis, D. Rossi, P. W. M. Johnson, M. Martelli, E. Zucca   +10 more
wiley   +1 more source

Wandering Lymphoma: A Case of Wandering Spleen Secondary to Splenic Marginal Zone Lymphoma. [PDF]

Case Rep Hematol
Parker JB, Wilson C, Parrondo R, Alhaj Moustafa M.   +3 more
europepmc   +1 more source

Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance

British Journal of Haematology, EarlyView.
Summary Response assessment in diffuse large B‐cell lymphoma (DLBCL) has traditionally relied on anatomical and metabolic imaging, with fluorodeoxyglucose positron emission tomography (FDG‐PET)–defined complete metabolic remission representing the principal end‐point of first‐line therapy. However, growing evidence indicates that metabolic control does
Santino Caserta, Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Mamdouh Skafi, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma. [PDF]

Front Immunol
Zhan Z, Li P, Liu Y, Zhen C, Zhang Y, Bai O.   +5 more
europepmc   +1 more source

Dupilumab as an Effective Adjuvant Therapy for Corticosteroid‐Refractory Lichenoid‐Bullous Dermatitis Secondary to Pembrolizumab

Australasian Journal of Dermatology, EarlyView.
Brandon Tan, Gaurav N. Pathak, Alexis Lara Rivero   +2 more
wiley   +1 more source